Airway Therapeutics closed a $50 million equity round to fund Phase 2b/3 development of zelpultide alfa and related manufacturing work.
- Amount
- $50M
- Stage
- Series E
- Announced
- 25 August 2026
- Investors
- Cincinnati Children's
- Use of funds
- Completing the Phase 2b portion of the Phase 2b/3 trial for BPD prevention, plus CMC and analytical activities.
- Checked
- Announced by the company